Metformin inhibits 7,12-dimethylbenz[a]anthracene-induced breast carcinogenesis and adduct formation in human breast cells by inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor signaling pathway

Toxicology and Applied Pharmacology

Volumn 284, Issue 2, 2015, Pages 217-226

  Maayah, Zaid H ^a   Ghebeh, Hazem ^b   Alhaider, Abdulqader A ^a,c   El Kadi, Ayman O S ^d   Soshilov, Anatoly A ^e   Denison, Michael S ^e   Ansari, Mushtaq Ahmad ^a   Korashy, Hesham M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AhR; Breast cancer; Cytochrome P4501A1; DNA damage; MCF10A cells; Metformin

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; 7,12-DIMETHYLBENZ(A)ANTHRACENE-DNA ADDUCT; 8-HYDROXYGUANINE; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CYTOCHROME P450 1A1; DNA ADDUCT; GUANINE; MESSENGER RNA; METFORMIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CARCINOGENESIS; CHEMICALLY INDUCED; DNA ADDUCT; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOGENS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; FEMALE; GUANINE; HUMANS; METFORMIN; MICE; NAD(P)H DEHYDROGENASE (QUINONE); RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84932096687     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.02.007     Document Type: Article

References (57)

1. Aljada A., Mousa S.A. Metformin and neoplasia: implications and indications. Pharmacol. Ther. 2012, 133:108-115.
2. Anon Cancer: lower risk of breast cancer in women with diabetes mellitus treated with metformin. Nat. Rev. Endocrinol. 2012, 8:508.
3. Anwar-Mohamed A., El-Kadi A.O. Down-regulation of the detoxifying enzyme NAD(P)H:quinone oxidoreductase 1 by vanadium in Hepa 1c1c7 cells. Toxicol. Appl. Pharmacol. 2009, 236:261-269.
4. Asensio-Lopez M.C., Lax A., Pascual-Figal D.A., Valdes M., Sanchez-Mas J. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic. Biol. Med. 2011, 51:1861-1871.
5. Braithwaite E., Wu X., Wang Z. Repair of DNA lesions induced by polycyclic aromatic hydrocarbons in human cell-free extracts: involvement of two excision repair mechanisms in vitro. Carcinogenesis 1998, 19:1239-1246.
6. Buters J.T., Sakai S., Richter T., Pineau T., Alexander D.L., Savas U., Doehmer J., Ward J.M., Jefcoate C.R., Gonzalez F.J. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1977-1982.
7. Chen X.L., Kunsch C. Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr. Pharm. Des. 2004, 10:879-891.
8. Chidambaram N., Baradarajan A. Influence of selenium on glutathione and some associated enzymes in rats with mammary tumor induced by 7,12-dimethylbenz(a)anthracene. Mol. Cell. Biochem. 1996, 156:101-107.
9. Ciolino H.P., Daschner P.J., Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998, 58:5707-5712.
10. Col N.F., Ochs L., Springmann V., Aragaki A.K., Chlebowski R.T. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res. Treat. 2012, 135:639-646.
11. Denison M.S., Harper P.A., Okey A.B. Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Codistribution of unoccupied receptor with cytosolic marker enzymes during fractionation of mouse liver, rat liver and cultured Hepa-1c1 cells. Eur. J. Biochem. 1986, 155:223-229.
12. Denison M.S., Fisher J.M., Whitlock J.P. Protein-DNA interactions at recognition sites for the dioxin-Ah receptor complex. J. Biol. Chem. 1989, 264:16478-16482.
13. Dias M., Cabrita S., Sousa E., Franca B., Patricio J., Oliveira C. Benign and malignant mammary tumors induced by DMBA in female Wistar rats. Eur. J. Gynaecol. Oncol. 1999, 20:285-288.
14. El Gendy M.A., Soshilov A.A., Denison M.S., El-Kadi A.O. Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms. Food Chem. Toxicol. 2012, 50:353-362.
15. Fontaine F., Delescluse C., de Sousa G., Lesca P., Rahmani R. Cytochrome 1A1 induction by primaquine in human hepatocytes and HepG2 cells: absence of binding to the aryl hydrocarbon receptor. Biochem. Pharmacol. 1999, 57:255-262.
16. Gharavi N., El-Kadi A.O. tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand. Drug Metab. Dispos. 2005, 33:365-372.
17. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45:51-88.
18. Hosono K., Endo H., Takahashi H., Sugiyama M., Uchiyama T., Suzuki K., Nozaki Y., Yoneda K., Fujita K., Yoneda M., Inamori M., Tomatsu A., Chihara T., Shimpo K., Nakagama H., Nakajima A. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol. Carcinog. 2010, 49:662-671.
19. Hwang E.S., Bowen P.E. DNA damage, a biomarker of carcinogenesis: its measurement and modulation by diet and environment. Crit. Rev. Food Sci. Nutr. 2007, 47:27-50.
20. Jaiswal A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med. 2004, 36:1199-1207.
21. Kennedy S.W., Lorenzen A., James C.A., Collins B.T. Ethoxyresorufin-O-deethylase and porphyrin analysis in chicken embryo hepatocyte cultures with a fluorescence multiwell plate reader. Anal. Biochem. 1993, 211:102-112.
22. Korashy H.M., El-Kadi A.O. Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology 2004, 201:153-172.
23. Korashy H.M., El-Kadi A.O. Transcriptional regulation of the NAD(P)H:quinone oxidoreductase 1 and glutathione S-transferase ya genes by mercury, lead, and copper. Drug Metab. Dispos. 2006, 34:152-165.
24. Korashy H.M., El-Kadi A.O. The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab. Rev. 2006, 38:411-450.
25. Korashy H.M., Shayeganpour A., Brocks D.R., El-Kadi A.O. Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol. Sci. 2007, 97:32-43.
26. Korashy H.M., Anwar-Mohamed A., Soshilov A.A., Denison M.S., El-Kadi A.O. The p38 MAPK inhibitor SB203580 induces cytochrome P450 1A1 gene expression in murine and human hepatoma cell lines through ligand-dependent aryl hydrocarbon receptor activation. Chem. Res. Toxicol. 2011, 24:1540-1548.
27. Korashy H.M., Maayah Z.H., Abd-Allah A.R., El-Kadi A.O., Alhaider A.A. Camel milk triggers apoptotic signaling pathways in human hepatoma HepG2 and breast cancer MCF7 cell lines through transcriptional mechanism. J. Biomed. Biotechnol. 2012, 2012:593195.
28. Lee J.M., Johnson J.A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 2004, 37:139-143.
29. Leung H.Y., Yung L.H., Shi G., Lu A.L., Leung L.K. The red wine polyphenol resveratrol reduces polycyclic aromatic hydrocarbon-induced DNA damage in MCF-10A cells. Br. J. Nutr. 2009, 102:1462-1468.
30. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
31. Long D.J., Waikel R.L., Wang X.J., Roop D.R., Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J. Natl. Cancer Inst. 2001, 93:1166-1170.
32. Lorenzen A., Kennedy S.W. A fluorescence-based protein assay for use with a microplate reader. Anal. Biochem. 1993, 214:346-348.
33. Ma Q., Kinneer K., Bi Y., Chan J.Y., Kan Y.W. Induction of murine NAD(P)H:quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzo-p-dioxin requires the CNC (cap 'n' collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduction. Biochem. J. 2004, 377:205-213.
34. Marchand A., Barouki R., Garlatti M. Regulation of NAD(P)H:quinone oxidoreductase 1 gene expression by CYP1A1 activity. Mol. Pharmacol. 2004, 65:1029-1037.
35. Martin S.A., McCarthy A., Barber L.J., Burgess D.J., Parry S., Lord C.J., Ashworth A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 2009, 1:323-337.
36. Miao W., Hu L., Scrivens P.J., Batist G. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J. Biol. Chem. 2005, 280:20340-20348.
37. Montano M.M., Chaplin L.J., Deng H., Mesia-Vela S., Gaikwad N., Zahid M., Rogan E. Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis. Oncogene 2007, 26:3587-3590.
38. Nebert D.W., Dalton T.P., Okey A.B., Gonzalez F.J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 2004, 279:23847-23850.
39. Nioi P., Hayes J.D. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 2004, 555:149-171.
40. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348(Pt 3):607-614.
41. Pasco D.S., Boyum K.W., Merchant S.N., Chalberg S.C., Fagan J.B. Transcriptional and post-transcriptional regulation of the genes encoding cytochromes P-450c and P-450d in vivo and in primary hepatocyte cultures. J. Biol. Chem. 1988, 263:8671-8676.
42. Pinaire J.A., Xiao G.H., Falkner K.C., Prough R.A. Regulation of NAD(P)H:quininone oxidoreductase by glucocorticoids. Toxicol. Appl. Pharmacol. 2004, 199:344-353.
43. Radjendirane V., Jaiswal A.K. Antioxidant response element-mediated 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induction of human NAD(P)H:quinone oxidoreductase 1 gene expression. Biochem. Pharmacol. 1999, 58:1649-1655.
44. Rogers J.M., Denison M.S. Analysis of the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human ovarian carcinoma BG-1 cells. Mol. Pharmacol. 2002, 61:1393-1403.
45. Sahin K., Tuzcu M., Sahin N., Akdemir F., Ozercan I., Bayraktar S., Kucuk O. Inhibitory effects of combination of lycopene and genistein on 7,12-dimethyl benz(a)anthracene-induced breast cancer in rats. Nutr. Cancer 2011, 63:1279-1286.
46. Shankar B., Kumar S.S., Sainis K.B. Generation of reactive oxygen species and radiation response in lymphocytes and tumor cells. Radiat. Res. 2003, 160:478-487.
47. Sheweita S.A., Tilmisany A.K. Cancer and phase II drug-metabolizing enzymes. Curr. Drug Metab. 2003, 4:45-58.
48. Shimada T., Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 2004, 95:1-6.
49. Shin S., Wakabayashi N., Misra V., Biswal S., Lee G.H., Agoston E.S., Yamamoto M., Kensler T.W. NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis. Mol. Cell. Biol. 2007, 27:7188-7197.
50. Sogawa K., Fujii-Kuriyama Y. Ah receptor, a novel ligand-activated transcription factor. J. Biochem. (Tokyo) 1997, 122:1075-1079.
51. Wahdan-Alaswad R., Fan Z., Edgerton S.M., Liu B., Deng X.S., Arnadottir S.S., Richer J.K., Anderson S.M., Thor A.D. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 2013, 12:3759-3769.
52. Whitelaw M.L., Gustafsson J.A., Poellinger L. Identification of transactivation and repression functions of the dioxin receptor and its basic helix-loop-helix/PAS partner factor Arnt: inducible versus constitutive modes of regulation. Mol. Cell. Biol. 1994, 14:8343-8355.
53. Wilcock C., Bailey C.J. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994, 24:49-57.
54. Will Y., Dykens J.A., Nadanaciva S., Hirakawa B., Jamieson J., Marroquin L.D., Hynes J., Patyna S., Jessen B.A. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 2008, 106:153-161.
55. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-268.
56. Zhuang Y., Miskimins W.K. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol. Cancer Res. 2011, 9:603-615.
57. Zientek-Targosz H., Kunnev D., Hawthorn L., Venkov M., Matsui S., Cheney R.T., Ionov Y. Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: a model for identifying candidate breast-tumor suppressors. Mol. Cancer 2008, 7:51.